Introduction {#Sec1}
============

In clinical trials of patients with type 2 diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have been shown to provide effective glycemic control when used in combination with oral antidiabetic drugs (OADs) \[[@CR1]\]. However, data regarding the use of GLP-1 receptor agonists in clinical practice are scarce. Here, the authors report data from the use of the once-daily human GLP-1 analog liraglutide in clinical practice.

Liraglutide is a once-daily human GLP-1 analog with 97% amino acid sequence identity to native GLP-1 \[[@CR2]\]. In phase 3 trials, liraglutide has been found to provide glycemic control alongside potential beneficial effects on body weight, reductions in systolic blood pressure (SBP), and improved beta-cell function \[[@CR3]--[@CR9]\]. Liraglutide treatment has also been found to be associated with a low risk of hypoglycemia, particularly when used without concomitant sulfonylurea treatment \[[@CR3]--[@CR9]\]. Liraglutide 1.2 mg is recommended by the UK National Institute for Health and Clinical Excellence (NICE) for use in certain patients as second-line therapy (in combination with metformin or sulfonylurea) or third-line therapy (in combination with metformin + sulfonylurea, or metformin + thiazolidinedione) \[[@CR10]\].

The authors aimed to assess the clinical effectiveness of liraglutide, from treatment initiation to first hospital visit, when prescribed at a center in Northern Ireland. The authors hypothesized that in a real-life clinical setting, despite the use of different background therapies, liraglutide treatment would result in comparable changes in HbA~1c~, body weight, and SBP to those observed in clinical trials.

Materials and Methods {#Sec2}
=====================

The authors assessed all patients who were prescribed liraglutide at Ulster Hospital from June 2009 to September 2010 and present data showing changes from baseline to the first hospital visit after initiation of liraglutide. In line with recommendations for initiating liraglutide and improving gastrointestinal (GI) tolerability, the starting dose of liraglutide was 0.6 mg daily. After 1 week, the dose was increased to 1.2 mg once daily. The primary endpoint assessed was change in glycated hemoglobin (HbA~1c~) from baseline to first clinic visit after the initiation of liraglutide. Data on body weight, SBP, hypoglycemia, and GI side effects were also assessed. Error is standard deviation (SD) unless otherwise stated. Stata 10 (StataCorp, 2007) was used to calculate means (SD) by summary descriptive statistics after data manipulation \[[@CR11]\]. No statistical tests were performed.

Results {#Sec3}
=======

Patient Demographics and Baseline Characteristics {#Sec4}
-------------------------------------------------

A total of 193 patients were included in the audit, 50 of whom (25.9%) were prescribed liraglutide off-license with existing insulin regimens (off-license use of liraglutide was initiated on investigator request and it was their sole responsibility). Among patients taking insulin in combination with liraglutide, 13 used basal insulin at baseline, 27 used basal--bolus regimens, and 10 used a premixed insulin. A total of 129 (66.8%) patients were male. The mean (SD) patient age was 55.8 (9.7) years, and mean (SD) duration of diabetes was 8.8 (5.4) years. Mean (SD) HbA~1c~ was 9.0 (1.5)%, SBP 133.5 (16.3) mmHg, and diastolic blood pressure 75.2 (9.5) mmHg. Mean (SD) cholesterol levels were 3.98 (0.89) mmol/L, low-density lipoprotein cholesterol 1.89 (0.76) mmol/L, high-density lipoprotein cholesterol 1.06 (0.25) mmol/L, and triglyceride levels were 2.46 (1.5) mmol/L. In line with recommendations \[[@CR10]\], liraglutide was initially prescribed at a dose of 0.6 mg to improve GI tolerability and the dose could be escalated to 1.2 mg after 1 week of treatment. The average time from treatment initiation to first post-initiation visit was 13.5 weeks. At the time of the first post-initiation visit, 174 (90.2%) patients were prescribed liraglutide 1.2 mg and 19 (9.8%) were receiving liraglutide 0.6 mg. No patients were prescribed liraglutide 1.8 mg at the first post-initiation visit.

Efficacy {#Sec5}
--------

From baseline, mean (SD) HbA~1c~ in the overall patient group (*n* = 193) reduced by 0.9 (1.1)%, from 9.0 (1.5)% to 8.1 (1.4)% (75 and 65 mmol/mol, respectively; Table [1](#Tab1){ref-type="table"}). Mean (SD) body weight decreased by 2.4 (7.3) kg from a baseline of 116.7 (24.0) kg to 114.4 (22.8) kg at the first post-initiation visit. In addition, mean (SD) SBP was reduced by 2.0 (±17.1) mmHg from a baseline of 133.5 (±16.3) mmHg to 131.0 (±16.2) mmHg at the first post-initiation visit. For patients using insulin (*n* = 50), the average insulin dose remained stable: mean basal doses were 70.6 and 70.0 U, and bolus doses were 79.4 and 76.3 U, at baseline and first visit, respectively. The insulin-treated group had a mean (SD) baseline HbA~1c~ of 9.2 (±1.3)% (77 mmol/mol) and a 0.8 (±1.1)% reduction was observed at the first post-initiation visit.Table 1Outcomes in patients prescribed liraglutide at the Ulster HospitalEfficacy endpointsBaselineFirst post-initiation visitChange from baselineHbA~1c~ (%) \[mmol/mol\]9.0 (1.5) \[75\]8.1 (1.4) \[65\]−0.9 (1.1) \[−9.8\]Body weight (kg)116.7 (24.0)114.4 (22.8)−2.4 (7.3)SBP (mmHg)133.5 (16.3)131.0 (16.2)−2.0 (17.1)DBP (mmHg)75.2 (9.5)75.5 (10.3)0.0 (10.4)Safety endpointsIncidence (%)Gastrointestinal effects11.9Minor hypoglycemia5.7Errors are SD*HbA*~*1c*~ Glycosylated hemoglobin, *DBP* diastolic blood pressure, *SBP* systolic blood pressure

Tolerability {#Sec6}
------------

Twenty-three (11.9%) patients experienced GI effects, a known side effect of liraglutide, and these were mainly transient. Eleven (5.7%) patients experienced minor hypoglycemia, nine (81.8%) of these were taking concomitant sulfonylureas and one (0.09%) was taking basal insulin.

Discussion {#Sec7}
==========

The changes observed here are comparable to those in phase 3 trials of liraglutide 1.2 mg in combination with OADs, in which HbA~1c~ decreases ranged from 1.0 to 1.5%, weight change from +0.3 to −2.9 kg, and SBP decreases from 0.6 to 6.7 mmHg following 26-week treatment \[[@CR3], [@CR4], [@CR6], [@CR9]\]. At 5.7%, the occurrence of minor hypoglycemia in this study also reflects data from phase 3 trials of patients using liraglutide 1.2 mg in combination with OADs \[[@CR3], [@CR4], [@CR6], [@CR9]\]. Limitations of the present study include its single-arm observational design, the absence of a fixed timeline for the first visit, and the fact that it was conducted at a single center. Furthermore, patients received concomitant medications that may have affected the measured outcomes, and these medications may have changed during the course of the study.

In this study, the insulin dose did not need to be reduced in patients who were using liraglutide with insulin. This observation is likely to be a reflection of the fact that initial glycemic control in these patients was poor. A clinical trial of the GLP-1 receptor agonist exenatide twice daily in combination with insulin also showed reductions in HbA~1c~ \[[@CR12]\], and another trial exploring the sequential addition to metformin of liraglutide and then insulin detemir also reported good glycemic control, sustained weight loss, and low rates of hypoglycemia \[[@CR13]\]. Based on these data, in Europe, exenatide twice daily is licensed for use in combination with basal insulin, and insulin detemir can be added to existing liraglutide therapy \[[@CR14], [@CR15]\]. It should be remembered that the addition of liraglutide to basal insulin is off-license, but if the combination is prescribed, the insulin dose should be monitored to minimize hypoglycemia; in the trial combining exenatide with insulin, patients with HbA~1c~ ≤8.0% (64 mmol/mol) had their insulin dose reduced by 20% during the addition of exenatide treatment \[[@CR10]\].

In conclusion, the data reported here show that results from clinical trials of liraglutide translate into real-life clinical practice. Liraglutide was well tolerated with a low incidence of hypoglycemia. Liraglutide improved glycemic control, body weight, and SBP, indicating that liraglutide is effective in a real-life setting.
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